Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download Gene or locus
Document related concepts
no text concepts found
Transcript
Gene or locus Polymorphism Risk of Progression Cases Reference Figl A, Mutat Res 2009, 661:78-84 rs1130409 (T>G, D148E) - Unchanged - 929 - ATG (+3 after nucleotide 94, exon 1) CGG>CGA (codon 444, exon 11) Unchanged Unchanged 38 38 G468S (exon 11) Unchanged 219 G468S (exon 11) Unchanged 71 G468S/G469V (exon 11) Unchanged 109 T1796A (V599E/K, exon 15) Unchanged 60 Kirschner M, Melanoma Res 2005, 15:427-34 T1796A (V599E/K, exon 15) Unchanged 50 Deichmann M, Oncology 2004, 66:411-9 T1796A (V599E/K, exon 15) Unchanged 71 Omholt K, Clin Cancer Res 2003, 9:6483-8 T1796A (V599E/K, exon 15) Unchanged 60 Deichmann M, BMC Cancer. 2005 Jun 3;5:58 T1796A/g1795A (V599E/K, exon 15) Increased 54 Kirschner M, Melanoma Res 2005, 15:427-34 T1799A (V600E, exon 15) Increased 56 Narita N, Oncogene 2009, Epub ahead of print T1799A (V600E, exon 15) Unchanged 219 T1799A (V600E, exon 15) Unchanged 109 T1799A (V600E, exon 15) Unchanged 18 Akslen LA, J Invest Dermatol 2005, 125:312-7 T1799A (V600E, exon 15) Unchanged 38 Kumar R, J Invest Dermatol 2004, 122:342-8 Increased - 122a - Rodero M, J Dermatol Sci 2007, 46:72-6 Chemokine (C-C motif) ligand 2 –2578 A>G [GG] - CCR5 Δ32 (32 bp deletion) Unchanged 782 Chemokine (C-C motif) receptor 5 Δ32 (32 bp deletion) Unchanged 125a Ugurel S, Cancer Immunol Immunother 2008, 57:685-91 Rodero M, J Dermatol Sci 2007, 46:72-6 CD28 rs1181388 (G>A) Unchanged 587 CD28 molecule rs1181390 (G>T) Unchanged 587 rs3116494 (A>G) Unchanged 587 rs3116496 (IVS3 + 17, T>C) Unchanged 587 rs3181098 (G>A, AG+AA) Decreased 587 rs3181100 (C>G) Unchanged 587 APEX1 APEX nuclease (multifunctional DNA repair enzyme) 1 (APE-1) BRAF v-raf murine sarcoma viral oncogene homolog B1 CCL2 Kumar R, J Invest Dermatol 2004, 122:342-8 Kumar R, J Invest Dermatol 2004, 122:342-8 Edlundh-Rose E, Melanoma Res 2006, 16:4718 Omholt K, Clin Cancer Res 2003, 9:6483-8 Ugurel S, Plos One 2007, 2:e236 Edlundh-Rose E, Melanoma Res 2006, 16:4718 Ugurel S, Plos One 2007, 2:e236 - Bouwhuis MG, Cancer Immunol 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol 2009, Epub ahead of print Immunother Immunother Immunother Immunother Immunother Immunother rs3181101 (C>G) Unchanged 587 rs3181107 (A>G) Unchanged 587 rs17533594 (A>G) Unchanged 587 CDKN2A 580 C>T (3’ UTR) Increased 59 Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) A148T (c.442 G>A, exon 2) Unchanged 285 Hypermethylation (promoter) Increased 71 Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Sauroja I, Genes Chromosomes Cancer 2000, 28:404-14 Lamperska KM, Acta Biochim Pol 2007, 54:11924 Straume O, Am J Pathol 2002, 161:229-37 LOH at D9S942 Increased 39 Cachia AR, Clin Cancer Res 2000, 6:3511-5 LOH at D9S974, D9S736, D9S1870, D9S171 Unchanged 50 Straume O, Am J Pathol 2002, 161:229-37 Nt500c>g (3’ UTR) Unchanged 185 Straume O, Am J Pathol 2002, 161:229-37 Nt500c>g (3’ UTR) Unchanged 285 Nt540c>t (3’ UTR) Decreased 185 Lamperska KM, Acta Biochim Pol 2007, 54:11924 Straume O, Am J Pathol 2002, 161:229-37 Nt540c>t (3’ UTR) Increased 59 null (deletion) Increased 190 CTLA4 rs231775 (CT42, A>G) Unchanged 587 Cytotoxic T-lymphocyte-associated protein 4 rs231777 (C>T) Unchanged 587 rs3087243 (CT60, G>A) Unchanged 587 rs5742909 (CT44, C>T) Unchanged 587 rs7665213 (JO30, G>A) Unchanged 587 rs11571297 (JO27, T>C) Unchanged 587 rs11571302 (JO31, G>T) Unchanged 587 rs11571319 (CT61, G>A) Unchanged 587 rs16840252 (C>T) Unchanged 587 Chemokine (C-X3-C motif) receptor 1 T280 (c.931C>T, rs3732378) V249I (c.837 G>A, rs3732379) Unchanged Unchanged 127a 127a DDIT3 null (gene deletion) Increased 106 DNA-damage-inducible transcript 3 (GADD153) - - EGF rs4444903 (A61G, 5’ UTR, AluI) rs4444903 (A61G, 5’ UTR, AluI, GG) Unchanged Increased CX3CR1 Epidermal growth factor 418 130 Sauroja I, Genes Chromosomes Cancer 2000, 28:404-14 Straume O, Am J Pathol 2002, 161:229-37 Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Rodero M, J Dermatol Sci 2007, 46:72-6 Rodero M, J Dermatol Sci 2007, 46:72-6 Korabiowska 17:805-11 - M, Histol Histopathol 2002, Casula M, BMC Dermatol 2009, 9:7 Okamoto I, J Invest Dermatol 2006, 126:2242-6 rs4444903 (A61G, 5’ UTR, AluI, GG) Increased 135 Shahbazi M, Lancet 2002, 359:397-401 rs4444903 (A61G, 5’ UTR, AluI, G-allele) Increased 135 Shahbazi M, Lancet 2002, 359:397-401 rs4444903 (A61G, 5’ UTR, AluI, GG) Increased 159 McCarron SL, Int J Cancer 2003, 107:673-5 rs4444903 (A61G, 5’ UTR, AluI, GG) Increased 753 James MR, J Invest Dermatol 2004, 123:760-2 rs4444903 (A61G, 5’ UTR, AluI) Unchanged 330 Amend KL, Cancer Res 2004, 64:2668-72 Codon 118 - Unchanged - 90 - Liu D, Clin Cancer Res 2005, 11:1237-46 rs 2228527 (A3716G, Arg1213Gly) rs 4253211 (G3768C, Arg1230Pro) Unchanged Unchanged 1238 1238 −1377 G>A (promoter) −670 A>G (promoter, AA+AG) Unchanged Increased 229 229 Zhang H, Cancer J 2007, 13:233-7 −844 T>C (promoter) - Unchanged - 229 - Zhang H, Cancer J 2007, 13:233-7 rs351855 (Gly388Arg) - Increased - 322 - Streit S, Br J Cancer 2006, 94:1879-86 GRB2-associated binding protein 2 Amplification and/or overexpression (locus 11q14.1) - Increased - 79 - GADD45A null (gene deletion) Increased 106 Growth arrest and DNA-damageinducible, alpha (GADD45) - - GSTM1 null (gene deletion) - Increased - 154 - Bu H, Oncol Rep 2007, 17:859-64 BsmAI (A>G, Ile>Val) - Unchanged - 154 - Bu H, Oncol Rep 2007, 17:859-64 null (gene deletion) - Unchanged - 154 - Bu H, Oncol Rep 2007, 17:859-64 Increased 152 Okamoto I, Int J Cancer 2006, 119:1312-5 Unchanged 152 Okamoto I, Int J Cancer 2006, 119:1312-5 ERCC1 Excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence) ERCC6 Excision repair cross-complementing rodent repair deficiency, complementation group 6 (CSB) FAS Fas (TNF receptor member 6, CD95) superfamily, FASLG Fas ligand (TNF superfamily, member 6, CD95 ligand) FGFR4 Fibroblast growth factor receptor 4 GAB2 Glutathione S-transferase mu 1 GSTP1 Glutathione S-transferase pi 1 GSTT1 Glutathione S-transferase theta 1 HMOX1 Heme oxygenase (decycling) 1 (HO-1) Short (<25) vs Long GT repeats (promoter, Short homozygous, microsatellite polymorphism, SS) Short (<25) vs Long GT repeats (promoter, Short homozygous, microsatellite polymorphism) b - - Millikan RC, Carcinogenesis 2006, 27:610-8 Millikan RC, Carcinogenesis 2006, 27:610-8 Zhang H, Cancer J 2007, 13:233-7 - Horst B, Am J Pathol 2009, 174:1524-33 Korabiowska 17:805-11 - M, Histol Histopathol - - - 2002, 5 cell lines - KISS1 null (gene deletion) Increased KiSS-1 metastasis-suppressor - - ICAM1 G241R (c.G721A, exon 4, GG) Decreased 164 Howell WM, Int J Immunogenet 2005, 32:367-73 Intercellular adhesion molecule 1 (CD54) K469E (c.A1405G, exon 6) Unchanged 164 Howell WM, Int J Immunogenet 2005, 32:367-73 ICOS rs4335928 (T>C) Unchanged 587 Inducible T-cell co-stimulator rs4521021 (T>C) Unchanged 587 rs4675374 (C>T) Unchanged 587 rs7602383 (A>G) Unchanged 587 rs10172036 (G>T) Unchanged 587 rs10183087 (A>C) Unchanged 587 rs10932029 (+173, T>C) Unchanged 587 rs10932036 (A>T) Unchanged 587 rs11571323 (G>A, AA) Increased 587 rs12466129 (T>A) Unchanged 587 +874 T/A (intron 1, TT) +874 T/A (intron 1) Increased Unchanged 90 42 Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Bouwhuis MG, Cancer Immunol Immunother 2009, Epub ahead of print Liu D, Clin Cancer Res 2005, 11:1237-46 +874 T/A (intron 1) Unchanged 169 −511 T>C (TT) −35 T>C Decreased Unchanged 169 169 Howell WM, Eur J Immunogenet, 30:409-414 −330 T>G - Unchanged - 169 - Howell WM, Eur J Immunogenet, 30:409-414 Unchanged - 169 - Howell WM, Eur J Immunogenet, 30:409-414 Interleukin 4 −590 T>C - IL6 −174 G/C (promoter) Unchanged 42 Interleukin 6 (interferon, beta 2) −174 G/C (promoter) Unchanged 169 Martínez-Escribano JA, Melanoma Res 2002, 12:465-9 Howell WM, Eur J Immunogenet, 30:409-414 IL8 Unchanged - 169 Howell WM, Eur J Immunogenet, 30:409-414 Interleukin 8 −251 T>A - IL10 −1082 G/A (promoter, AA) Increased 16 IFNG Interferon, gamma IL1B Interleukin 1, beta IL2 Interleukin 2 IL4 Lee JH, J Natl Cancer Inst 1996, 88:1731-7 - Martínez-Escribano JA, Melanoma Res 2002, 12:465-9 Howell WM, Eur J Immunogenet, 30:409-414 Howell WM, Eur J Immunogenet, 30:409-414 - - - von Euw EM, J Transl Med 2008, 6:6 −1082 G/A (promoter) Unchanged 90 Liu D, Clin Cancer Res 2005, 11:1237-46 −1082 G/A (promoter) Unchanged 98 Alonso R, Melanoma Res 2005, 15:53-60 −1082 G/A (promoter, AA) Increased 165 −819 C/T (promoter) Unchanged 98 −819 C/T (promoter) Unchanged 165 −592 C/A (promoter) Unchanged 98 −592 C/A (promoter) Unchanged 165 Howell WM, Genes and Immunity 2001, 2:25-31 ATA haplotype (at positions −1082 G/A, −819 C/T, − 592 C/A) ACC/ACC, ACC/ATA, ATA/ATA haplotypes (at positions −1082 G/A, −819 C/T, −592 C/A) ACC/ATA haplotypes (at positions −1082 G/A, −819 C/T, −592 C/A) A1188C - Unchanged 108 Vuoristo MS, Cancer Genet Cytogenet 2007, 176:54-7 Increased 165 Howell WM, Genes and Immunity 2001, 2:25-31 Increased 42 Martínez-Escribano JA, Melanoma Res 2002, 12:465-9 Unchanged - 169 - Howell WM, Eur J Immunogenet, 30:409-414 +252 G/A - Unchanged - 146 - Howell WM, Eur J Immunogenet 2002, 29:17-23 LZTS1 Null (gene deletion, 8p22) Increased Leucine zipper, putative tumor suppressor 1 - - MC1R Any variant NRHC alleles (V60L, V92M, I155T, R163Q) Increased Increased 147 147 Landi MT, J Natl Cancer Inst 2005, 97:998-1007 One or more RHC alleles (D84E, R142H, R151C, R160W, D294H) Two variants (RHC/RHC, NRHC/NRHC, RHC/NRHC) null (6q22.33-q24.1, gene deletion) - Increased 147 Landi MT, J Natl Cancer Inst 2005, 97:998-1007 Increased 147 Landi MT, J Natl Cancer Inst 2005, 97:998-1007 Increased - 20 - Amplification (locus 3p13-3p14) - Increased - 206 - Garraway LA, Nature 2005, 436:117-22 1G/2G (-1607, promoter, 5’-GGA-3’, 2G) Increased 8 cell lines Rutter JL, Cancer Res 1998, 58:5321-5 Interleukin 10 IL12A Interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1, p35) (IL12) LTA Lymphotoxin alpha (TNF superfamily, member 1) Melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor) MED23 Mediator complex subunit 23 (CRSP3) MITF Microphthalmia-associated transcription factor MMP1 53 (uveal) - Howell WM, Genes and Immunity 2001, 2:25-31 Alonso R, Melanoma Res 2005, 15:53-60 Howell WM, Genes and Immunity 2001, 2:25-31 Alonso R, Melanoma Res 2005, 15:53-60 - Onken MD, Clin Cancer Res 2008, 14:3737-45 - Landi MT, J Natl Cancer Inst 2005, 97:998-1007 Goldberg SF, Cancer Res 2003, 63:432-40 - - Matrix metallopeptidase 1 (interstitial collagenase) 1G/2G (-1607, promoter, 5’-GGA-3’, 2G) Increased 139 MMP2 rs243865 (-1306 C/T) rs2285053 (-735 C/T) Unchanged Unchanged 1002 1002 Cotignola J, J Negat Results Biomed 2007, 6:9 rs3025058 (-1171 5A/6A) - Unchanged - 1002 - Cotignola J, J Negat Results Biomed 2007, 6:9 rs2250889 (P574R, C>G) rs2274756 (R668Q, G>A) Unchanged Unchanged 538 1002 Cotignola J, BMC Med Genet 2007, 8:10 rs2664538 (Q279R, A>G) Unchanged 1002 Cotignola J, BMC Med Genet 2007, 8:10 rs3918242 (-1562, C>T) Unchanged 1002 Cotignola J, BMC Med Genet 2007, 8:10 rs3918252 (N127K, C>G) Unchanged 538 Cotignola J, BMC Med Genet 2007, 8:10 rs8125581 (D165N, G>A) Unchanged 538 Cotignola J, BMC Med Genet 2007, 8:10 NFKB1 ATTG1/ATTG1 genotype (-94insATTG, promoter) Decreased 185 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 - - Bu H, J Cancer Res Clin Oncol 2007, 133:85966 - NME1 null (gene deletion) - Increased - 33 - G12D or G13D/R (exon 1) G12D or G13D/R (exon 1) Decreased Unchanged 109 18 G12D or G13D/R (exon 1) Unchanged 38 Kumar R, J Invest Dermatol 2004, 122:342-8 CAA(Gln)>AAA(Lys)/CGA(Arg)/CAT(His)/TTA(Leu) (codon 61, exon 2) CAA(Gln)>AAA(Lys)/CGA(Arg)/CAT(His)/TTA(Leu) (codon 61, exon 2) CAA(Gln)>AAA(Lys)/CGA(Arg)/CAT(His)/TTA(Leu) (codon 61, exon 2) CAA(Gln)>AAA(Lys)/CGA(Arg)/CAT(His)/TTA(Leu) (codon 61, exon 2) CAA(Gln)>AAA(Lys)/CGA(Arg)/CAT(His)/TTA(Leu) (codon 61, exon 2) or R68T CAA(Gln)>AAA(Lys)/CGA(Arg) (codon 61, exon 2) Increased 88 Omholt K, Clin Cancer Res 2002, 8:3468-74 Unchanged 219 Unchanged 18 Akslen LA, J Invest Dermatol 2005, 125:312-7 Unchanged 71 Omholt K, Clin Cancer Res 2003, 9:6483-8 Decreased 109 Unchanged 38 PPP1R15A null (gene deletion) Increased 106 Protein phosphatase 1, regulatory (inhibitor) subunit 15A (GADD34) - - Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) MMP3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) MMP9 Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) Non-metastatic cells 1, protein (NM23A) expressed in (NM23) NRAS Neuroblastoma RAS viral (v-ras) oncogene homolog - - Ye S, Cancer Res 2001, 61:1296-8 Cotignola J, J Negat Results Biomed 2007, 6:9 - Cotignola J, BMC Med Genet 2007, 8:10 Flørenes VA, Cancer Res 1992, 52:6088-91 Ugurel S, Plos One 2007, 2:e236 Akslen LA, J Invest Dermatol 2005, 125:312-7 Edlundh-Rose E, Melanoma Res 2006, 16:4718 Ugurel S, Plos One 2007, 2:e236 Kumar R, J Invest Dermatol 2004, 122:342-8 Korabiowska 17:805-11 - M, Histol Histopathol 2002, Millikan RC, Carcinogenesis 2006, 27:610-8 rs1805329 (C1097T, Ala249Val) - Unchanged - 1238 - Unchanged - 56 - Narita N, Oncogene 2009, Epub ahead of print Ret proto-oncogene G691S - TGFB1 +915 G/C (Arg25>Pro, exon 1) Unchanged 169 Transforming growth factor, beta 1 - - Howell WM, Eur J Immunogenet 2003, 30:409414 - TNF −376 G/A (promoter) −308 G/A (promoter) Unchanged Unchanged 146 146 Howell WM, Eur J Immunogenet 2002, 29:17-23 −238 G/A (promoter) Unchanged 146 Howell WM, Eur J Immunogenet 2002, 29:17-23 FokI (exon 2, rs2228570, C>T, Met1Thr) FokI (exon 2, rs2228570, C>T, Met1Thr) Unchanged Unchanged 171 316 Halsall JA, Br J Cancer 2004, 91:765-70 GATA (A–1012G, exon 1a, promoter, rs4516035, AA) GATA (A–1012G, exon 1a, promoter, rs4516035, A allele) G–1520C (rs7139166, promoter, G allele) Increased 171 Hutchinson PE, Clin Cancer Res 2000, 6:498504 Halsall JA, Br J Cancer 2004, 91:765-70 Increased 157 Halsall JA, Dermatoendocrinol 2009, 1:54-7 Increased 157 Halsall JA, Dermatoendocrinol 2009, 1:54-7 TaqI (exon 9, rs731236, codon 352, T>C) Unchanged 171 Halsall JA, Br J Cancer 2004, 91:765-70 TaqI (exon 9, rs731236, codon 352, T>C, tt) Increased 316 FokI/TaqI Unchanged 171 Hutchinson PE, Clin Cancer Res 2000, 6:498504 Halsall JA, Br J Cancer 2004, 91:765-70 FokI/TaqI (tt/ff) Increased 316 GATA/ FokI (AAFF+AAff) Increased 171 Hutchinson PE, Clin Cancer Res 2000, 6:498504 Halsall JA, Br J Cancer 2004, 91:765-70 GATA/ G–1520C (AG) Increased 157 Halsall JA, Dermatoendocrinol 2009, 1:54-7 GATA/ G–1520C (AC/GG/GC) Unchanged 157 Halsall JA, Dermatoendocrinol 2009, 1:54-7 GATA/TaqI Unchanged 171 Halsall JA, Br J Cancer 2004, 91:765-70 VEGFA –2578 C>A Unchanged 152 Vascular endothelial growth factor A (VEGF) –1154 G>A (AA) Decreased 152 +405 G>C (exon 1) Unchanged 152 +936 T>C (exon 8) Unchanged 152 CAC haplotype (–2578 C>A, –1154 G>A, +405 G>C) rs2228001 (exon 16, A2920C, Lys939Gln) Decreased 152 Howell 232 Howell 232 Howell 232 Howell 232 Howell 232 Unchanged 1238 RAD23B RAD23 homolog B (S. cerevisiae) (HR23B, RD23B) RET Tumor necrosis factor (TNF superfamily, member 2) (TNF-alpha) VDR Vitamin D (1,25- dihydroxyvitamin D3) receptor XPC - - - Howell WM, Eur J Immunogenet 2002, 29:17-23 WM, Genes and Immunity 2002, 3: 229– WM, Genes and Immunity 2002, 3: 229– WM, Genes and Immunity 2002, 3: 229– WM, Genes and Immunity 2002, 3: 229– WM, Genes and Immunity 2002, 3: 229– Millikan RC, Carcinogenesis 2006, 27:610-8 Xeroderma pigmentosum C - - XPD rs13181 (exon 23, A35931C, PstI, Lys751Gln, Gln/ Gln) rs13181 (exon 23, A35931C, PstI, Lys751Gln) Increased Unchanged 90 rs13181 (exon 23, A35931C, PstI, Lys751Gln, Lys/ Gln) rs13181 (exon 23, A35931C, PstI, Lys751Gln, Gln/ Gln) rs1799793 (exon 10, G23529A, Asp312Asn, Asn/Asn) Two-SNP haplotype (rs13181 [C] and rs1799793 [A]) rs1799797 (T2063A) rs 1800067 (G17103A, Arg415Gln) Increased 244 Kertat K, Oncol Rep 2008, 20:179-83 Decreased 244 Kertat K, Oncol Rep 2008, 20:179-83 Increased 1238 Millikan RC, Carcinogenesis 2006, 27:610-8 Increased 1238 Millikan RC, Carcinogenesis 2006, 27:610-8 Unchanged Unchanged 1238 1238 Millikan RC, Carcinogenesis 2006, 27:610-8 rs17655 (exon 15, G3507C, NlaIII, Asp1104His) - Unchanged - 1238 - Millikan RC, Carcinogenesis 2006, 27:610-8 rs25487 (exon 10, G>A, MspI, R339Q, G28152A, AA) rs25487 (exon 10, G>A, MspI, R339Q, G28152A) Decreased 929 Unchanged 90 rs25489 (G>A, R280H) Unchanged 929 Figl A, Mutat Res 2009, 661:78-84 rs3213245 (–77 T>C, CC) Increased 929 Figl A, Mutat Res 2009, 661:78-84 Xeroderma pigmentosum D (ERCC2) XPF Xeroderma pigmentosum F (ERCC4, RAD1) XPG Xeroderma pigmentosum G (ERCC5) XRCC1 X-ray repair complementing defective repair in Chinese hamster cells 1 a b 28% familial melanoma cases all familial melanoma cases 1238 Millikan RC, Carcinogenesis 2006, 27:610-8 Liu D, Clin Cancer Res 2005, 11:1237-46 Millikan RC, Carcinogenesis 2006, 27:610-8 Figl A, Mutat Res 2009, 661:78-84 Liu D, Clin Cancer Res 2005, 11:1237-46
Related documents